Raging Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Raging Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,595	Closed	-$883K	–	16
2020 Q1	$883K	Buy	10,595 +4,955	+88%	+$697K	0.67%	18
2019 Q4	$953K	Hold	5,640	–	–	0.17%	31
2019 Q3	$1.05M	Buy	5,640 +976	+21%	+$189K	0.17%	43
2019 Q2	$1.07M	Hold	4,664	–	–	0.18%	36
2019 Q1	$980K	Sell	4,664 -17,230	-79%	-$3.23M	0.14%	41
2018 Q4	$2.52M	Buy	+21,894	New	+$3.24M	0.36%	45
2016 Q2	–	Sell	-11,055	Closed	-$1.59M	–	46
2016 Q1	$1.59M	Buy	+11,055	New	+$1.56M	0.24%	34
2015 Q4	–	Sell	-8,693	Closed	-$1.41M	–	39
2015 Q3	$1.41M	Sell	8,693 -700	-7%	-$151K	0.18%	46
2015 Q2	$2.42M	Buy	9,393 +3,146	+50%	+$751K	0.31%	38
2015 Q1	$1.41M	Buy	+6,247	New	+$1.31M	0.19%	35

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GAM

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Raging Capital Management's AXDX Position: Q2 2020 in Review

Raging Capital Management sold out of Accelerate Diagnostics (AXDX) in Q2 2020, closing a stake of 10,595 shares — an estimated $883K sold.

Raging Capital Management first reported a position in AXDX in Q1 2015 and held it in 10 quarters. The position peaked at $2.52M in Q4 2018. 123 funds tracked by Wall St. Rank hold AXDX as of Q2 2020.

Raging Capital Management reported no remaining Accelerate Diagnostics position as of Q2 2020 after selling out during the quarter.
Raging Capital Management sold 10,595 Accelerate Diagnostics shares in Q2 2020, an estimated $883K.
Raging Capital Management first reported a position in Accelerate Diagnostics in Q1 2015 and held it in 10 quarters.
Raging Capital Management's Accelerate Diagnostics position peaked at $2.52M in Q4 2018.
123 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2020.

Based on Raging Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.